福辛普利联合依帕司他片治疗糖尿病肾病的疗效观察
|
摘要
目的研究福辛普利联合依帕司他片治疗糖尿病肾病的疗效。方法选择2016年1月—2017年12月新疆喀什第三师医院收治的60例糖尿病肾病患者,随机分为两组。对照组口服依帕司他片治疗,每次50 mg,每天3次。观察组联合口服福辛普利钠片,每次20 mg,每天1次。两组均治疗4周。比较两组的疗效以及治疗前后的肾功能、氧化应激指标改变情况。结果观察组的有效率为86.67%,显著高于对照组的70.00%(P<0.05)。治疗后,两组患者的尿素氮(BUN)、24 h尿蛋白和血肌酐(Scr)均较治疗前显著降低(P<0.05),且观察组显著低于对照组(P<0.05)。治疗后两组的丙二醛(MDA)值较治疗前显著降低(P<0.05),总抗氧化能力(T-AOC)和超氧化物歧化酶(SOD)水平均较治疗前显著升高(P<0.05),且观察组显著优于对照组(P<0.05)。结论福辛普利联合依帕司他片在减少糖尿病肾病患者全身氧化应激、改善肾功能方面均具有积极作用,可显著提高疗效,值得应用推广。
Objective To investigate the effect of Epalrestat Tablets combined with fosinopril in treatment of diabetic nephropathy.Methods Selected 60 cases of patients with diabetic nephropathy who were treated in our hospital from January 2016 to December2017, divided into two groups randomly. The control group was treated with Epalrestat Tablets alone, and the observation group combined with oral Phu Simpson Leigh treatment. The curative effects of two groups were compared, and the changes of renal function and oxidative stress index before and after treatment were compared. Results The effective rate of the observation group was significantly higher than control group(P < 0.05). After treatment, BUN, 24-hour urinary protein and SCR in both groups were significantly decreased(P < 0.05), and those in the observation group were significantly lower(P < 0.05). After treatment, MDA values in both groups were significantly decreased(P < 0.05), T-AOC and SOD values were significantly increased(P < 0.05),especially in the observation group(P < 0.05). Conclusion Epalrestat tablets combined with fosinopril have positive effects on reducing systemic oxidative stress and improving renal function in patients with diabetic nephropathy, which can significantly improve the curative effect.
Objective To investigate the effect of Epalrestat Tablets combined with fosinopril in treatment of diabetic nephropathy.Methods Selected 60 cases of patients with diabetic nephropathy who were treated in our hospital from January 2016 to December2017, divided into two groups randomly. The control group was treated with Epalrestat Tablets alone, and the observation group combined with oral Phu Simpson Leigh treatment. The curative effects of two groups were compared, and the changes of renal function and oxidative stress index before and after treatment were compared. Results The effective rate of the observation group was significantly higher than control group(P < 0.05). After treatment, BUN, 24-hour urinary protein and SCR in both groups were significantly decreased(P < 0.05), and those in the observation group were significantly lower(P < 0.05). After treatment, MDA values in both groups were significantly decreased(P < 0.05), T-AOC and SOD values were significantly increased(P < 0.05),especially in the observation group(P < 0.05). Conclusion Epalrestat tablets combined with fosinopril have positive effects on reducing systemic oxidative stress and improving renal function in patients with diabetic nephropathy, which can significantly improve the curative effect.
引文
[1]魏晓,欧三桃.综合防治,延缓进展-2014年版《中国糖尿病肾病防治专家共识》解读[J].实用医学杂志, 2016,32(1):1-3.
[2]张瑶,汪力,高芳,等.阿托伐他汀对糖尿病肾病微炎症状态的影响[J].西部医学, 2016, 28(2):215-217.
[3]区洪炎,阮国梅,李志成,等.甘精胰岛素联合二甲双胍治疗初发早期糖尿病肾病的疗效[J].热带医学杂志,2017, 17(2):208-210.
[4]金洁娜,孙慧艳,徐赵钕,等.前列地尔治疗早期糖尿病肾病疗效及安全性观察[J].重庆医学, 2016, 45(10):1337-1338.
[5]中华医学会内分泌学分会.中国成人糖尿病肾脏病临床诊断的专家共识[J].糖尿病天地(临床), 2016, 31(6):379-385.
[6] Xue R, Gui D, Zheng L, et al. Mechanistic insight and management of diabetic nephropathy:recent progress and future perspective[J]. J Diabet Res, 2017, 2017(1,supplement 1):1839809.
[7]凌厉,劳国娟,陈立波,等.前列地尔对糖尿病肾病患者肾血流参数及纤维化指标的影响[J].海南医学院学报, 2016, 22(2):151-153.
[8]贾良勇,李慧,李刘倩,等.早期糖尿病肾病患者联合检测血清CysC与尿mALB/Cr的临床意义[J].中国实验诊断学, 2017, 21(2):238-240.
[9]刘成功.胱抑素C、同型半胱氨酸与早期糖尿病肾病的关系[J].中国现代药物应用, 2016, 10(4):18-19.
[10]孙晓丹,刁宗礼,刘旭,等.糖尿病肾病维持性血液透析患者死亡危险因素分析[J].临床和实验医学杂志,2017, 16(7):633-636.
[11]黎国红,贺嵘,秦齐齐.渴络欣胶囊联合替米沙坦治疗2型糖尿病肾病的疗效观察[J].现代药物与临床, 2016,31(9):1439-1442.
[12]王伟,卢志远,任稹,等.前列地尔与福辛普利联合治疗对糖尿病肾病患者肾功能、氧化应激的影响[J].海南医学院学报, 2016, 22(16):1796-1799.
[13]高雁鸿,王耀.福辛普利结合格列喹酮治疗糖尿病肾病的临床疗效及安全性观察[J].中国药物与临床,2017, 17(8):1218-1220.
[14]邹汶兵.前列地尔联合福辛普利治疗糖尿病肾病蛋白尿的临床疗效及安全性评价[J].中国临床药理学杂志,2016, 32(1):18-20.
[15]赵金香,李耀华,谢萍.黄葵胶囊对糖尿病肾病血液透析患者微炎症和氧化应激状态的影响[J].中国中医药信息杂志, 2017, 24(2):21-24.
[16]胡爱民,晏玲,张利芳,等.糖肾煎对2型糖尿病肾病大鼠氧化应激的影响[J].湖北中医药大学学报, 2016, 18(1):15-19.
[2]张瑶,汪力,高芳,等.阿托伐他汀对糖尿病肾病微炎症状态的影响[J].西部医学, 2016, 28(2):215-217.
[3]区洪炎,阮国梅,李志成,等.甘精胰岛素联合二甲双胍治疗初发早期糖尿病肾病的疗效[J].热带医学杂志,2017, 17(2):208-210.
[4]金洁娜,孙慧艳,徐赵钕,等.前列地尔治疗早期糖尿病肾病疗效及安全性观察[J].重庆医学, 2016, 45(10):1337-1338.
[5]中华医学会内分泌学分会.中国成人糖尿病肾脏病临床诊断的专家共识[J].糖尿病天地(临床), 2016, 31(6):379-385.
[6] Xue R, Gui D, Zheng L, et al. Mechanistic insight and management of diabetic nephropathy:recent progress and future perspective[J]. J Diabet Res, 2017, 2017(1,supplement 1):1839809.
[7]凌厉,劳国娟,陈立波,等.前列地尔对糖尿病肾病患者肾血流参数及纤维化指标的影响[J].海南医学院学报, 2016, 22(2):151-153.
[8]贾良勇,李慧,李刘倩,等.早期糖尿病肾病患者联合检测血清CysC与尿mALB/Cr的临床意义[J].中国实验诊断学, 2017, 21(2):238-240.
[9]刘成功.胱抑素C、同型半胱氨酸与早期糖尿病肾病的关系[J].中国现代药物应用, 2016, 10(4):18-19.
[10]孙晓丹,刁宗礼,刘旭,等.糖尿病肾病维持性血液透析患者死亡危险因素分析[J].临床和实验医学杂志,2017, 16(7):633-636.
[11]黎国红,贺嵘,秦齐齐.渴络欣胶囊联合替米沙坦治疗2型糖尿病肾病的疗效观察[J].现代药物与临床, 2016,31(9):1439-1442.
[12]王伟,卢志远,任稹,等.前列地尔与福辛普利联合治疗对糖尿病肾病患者肾功能、氧化应激的影响[J].海南医学院学报, 2016, 22(16):1796-1799.
[13]高雁鸿,王耀.福辛普利结合格列喹酮治疗糖尿病肾病的临床疗效及安全性观察[J].中国药物与临床,2017, 17(8):1218-1220.
[14]邹汶兵.前列地尔联合福辛普利治疗糖尿病肾病蛋白尿的临床疗效及安全性评价[J].中国临床药理学杂志,2016, 32(1):18-20.
[15]赵金香,李耀华,谢萍.黄葵胶囊对糖尿病肾病血液透析患者微炎症和氧化应激状态的影响[J].中国中医药信息杂志, 2017, 24(2):21-24.
[16]胡爱民,晏玲,张利芳,等.糖肾煎对2型糖尿病肾病大鼠氧化应激的影响[J].湖北中医药大学学报, 2016, 18(1):15-19.